[Anti-hypertensive therapy in pregnancy-induced hypertension with urapidil].
Urapidil is an antagonist of postsynaptic alpha 1 receptors, which leads to a diminution of the increased blood pressure by reducing the peripheral vascular resistance. With this pilot study we examined, whether it is possible to reduce the pregnancy-induced-hypertension with urapidil postpartum. The postpartum dosage of dihydralazine was diminished step by step and finally discontinued. We started i.v. treatment with urapidil at a diastolic blood pressure of more than 100 mm Hg. We observed a declining blood pressure in all cases without any tachycardia or serious side effects. Further studies will have to classify the rank of urapidil in the treatment of hypertension in preeclampsia.
Frauenklinik, Universität Heidelberg.
J
J
Wacker
J
J
Müller
E M
EM
Grischke
R
R
Unkels
G
G
Bastert
D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D015924:Blood Pressure Monitors; D004078:Dihydralazine / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007262:Infusions, Intravenous; D008431:Maternal-Fetal Exchange / Q000187:drug effects; D010865:Pilot Projects; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011225:Pre-Eclampsia / Q000188:drug therapy*; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy*; D011644:Puerperal Disorders / Q000188:drug therapy
D000959:Antihypertensive Agents; D010879:Piperazines; C015568:urapidil; D004078:Dihydralazine
Antihypertensive Therapie bei schwangerschaftsinduzierter Hypertonie (SIH) mit Urapidil.